Construction of human liver cancer vascular endothelium cDNA expression library and screening of the endothelium-associated antigen genes

Figure 1 Cultured human liver cancer vascular endothelia. A: Morphology of cultured human liver cancer vascular endothelial cells; B: Uptake of Ac-LDL; C: Electron microscope for fenestration.

Figure 2 Immunofluorescence analysis of endothelial cells stained with the sera diluted 1:5000 isolated from the mice immunized with HLCVECs. A: HLCVECs; B: Activated HUVECs; C: HUVECs.

Figure 3 Inhibition of the HLCVECs proliferation by HLCVECs immunized murine serum from 1 of 6 immunized mice and 1 of 4 non-immunized mice. Points are the average of three wells.

Figure 4 Cell cycle analysis of HLCVECs after treatment with immune sera or non-immune sera. A: HLCVECs treated with immune sera for 6 h; B: HLCVECs treated with non-immune sera for 6 h.

Figure 5 Positive dots of phage clone of screening by immune sera. A: The first cycle of screening by immune sera; B: The second cycle of screening by immune sera.

Figure 6 Electrophoresis analysis of enzymatic digestion of SEREX positive clones. M, λHind III marker, from above to below: 20130, 9416, 6557, 4316, 2322, 2027, 564 bp; Lanes 1-8, positive clones digested with EcoR I and Xhol I.